Home' Australian Pharmacist : Australian Pharmacist June 2016 Contents Australian Pharmacist June 2016 I ©Pharmaceutical Society of Australia Ltd.
1. Briggs AM, Buchbinder, R. Back pain: a national health
priority area in Australia? MJA 2009; 190 (9):499–502.
2. Australian Institute of Health and Welfare. Back pain and
problems. 2015. At: www.aihw.gov.au/back-problems/
3. Wilk V, Palmer HD, Stosic RG, et al. Evidence and practice
in the self-management of low back pain: findings
from an Australian internet-based survey. Clin J Pain
4. MBF Foundation. The high price of pain: the economic
impact of persistent pain in Australia. 2007.
5. Pain Australia. National pain strategy. 2010. At: www.
6. Maher CG, Williams C, Lin C, et al. Managing low back pain
in primary care. Aust Prescr 2011;34:128–32.
7. NSW Agency for Clinical Innovation. Pain management network.
Assessment tools. 2016. At: www.aci.health.nsw.gov.au/chronic-
8. Kendall NAS, Linton SJ, Main, CJ (1997). Guide to assessing
psycho-social yellow flags in acute low back pain: risk
factors for long-term disability and work loss. Accident
compensation corporation and the New Zealand
guidelines group. Wellington. New Zealand. 2004.
9. Nicholas M, Molloy A, Brooker C. Using opioids with
persisting noncancer pain: a biopsychosocial persepective.
Clin J Pain 2006;22(2):137–46.
10. Dobbin M. Pharmaceutical drug misuse in Australia. Aust
Prescr 2014;37:79-81. At: www.australianprescriber.com/
11. Cogger S, Dietze P, Lloyd B. Victorian drug trends 2012. Findings
from the illicit drug reporting system (IDRS). Australian drug
trends series No. 94. Sydney. National Drug and Alcohol
Research Centre. University of New South Wales. 2013.
12. Hall K, Gibbie T, Lubman DI. Motivational inter viewing
techniques. AFP 2012;41(9):660–7. At: www.racgp.org.au/
13. Webster LR, Webster R. Predicting aberrant behaviors in
opioid treated patients: preliminary validation of the opioid
risk too. Pain Med 2005;6(6):432. At: www.drugabuse.gov/
14. Consumers, the health system and health literacy : Taking action
to improve quality and safety. Consultation Paper. Australia
Commission on Safety and Quality in Health Care. 2013.
15. The Department of Health. Chronic disease management
plan fact sheet. 2016. At: www.health.gov.au/internet/
References from Health Promotion CPD article on page 45.
From today, pharmacies across Australia are able to join a free program
focussed on supporting Australian community pharmacies with a range
of resources designed to improve long-term clinical outcomes for patients
with psoriasis. The Dermatology Network Pharmacy Program is supported
by LEO Pharma.
Due to a lack of education available
for patients in relation to prescribed
medications, psoriasis treatment is often
associated with poor clinical outcomes,
high levels of frustration and anxiety,
decreased adherence and worsening of
Dr Diana Rubel, Dermatologist, Woden,
ACT and Senior Lecturer, ANU said: ‘As
psoriasis has a chronic and relapsing
course, patients are likely to try a
range of treatments. It is important
for healthcare professionals to have
the right tools to aid discussions with
patients to reinforce appropriate use of
their treatments. This will lead to better
compliance and clinical results as well as
an improved overall quality of life.’
The LEO Pharma Dermatology
Network Pharmacy Program provides
pharmacists with access to resources
and education on psoriasis and the
opportunity to become part of a national
network of pharmacies. At the point of
prescribing, clinicians will be able to
use the pharmacy locator to identify
pharmacies that are part of the network,
and have implemented the program.
This will ensure patients are able to
locate pharmacies with the specialised
knowledge to expertly counsel them
across a range of dermatological issues
including psoriasis. Network pharmacies
have access to a number of resources that
they can use in counselling their patients.
Kos Sclavos, Professional Programs
Architect at Sinapse / PharmaPrograms
said: ‘The program was developed in
recognition that pharmacists want more
practical support in specialised areas
like dermatology, specifically psoriasis –
simple things like reinforcing the correct
amount of medicine to use and the best
way to apply the medicine can have
a huge impact on clinical outcomes.
The resources support the Quality
Use of Medicines and can be utilised
in performing a Clinical Intervention,
where appropriate under the 6CPA.’
Pharmacists key to
increasing use of LARCs
A report has called for an increased role
for pharmacists in supporting the use of
‘more effective and less user-dependent
methods of contraception’.
The Australian Healthcare and Hospitals
Association (AHHA) report, which was
funded by MSD in Australia, identified
pharmacy as an important channel to
facilitate greater use of long-acting
reversible contraceptive (LARC) methods,
such as contraceptive implants and
IMS data revealed that more than
700,000 emergency contraceptives were
dispensed in pharmacies last year.
The A Health System that Supports
Contraception Choice report
recommended that pharmacists play
a greater role in supporting equitable
access to LARC methods, specifically
through policies that:
Provide education on the provision of
effective and efficient counselling on
Promote models of care that
incorporate contraceptive counselling
into different (existing) services
provided in pharmacy, e.g. Supply of
emergency contraception, Clinical
Interventions, Staged Supply, HMRs,
opioid replacement therapy;
Help identify need in the local
population and support the
identification of referral pathways.
Pharmacists interviewed as part of the
research report agreed that opportunities
exist for greater involvement in
contraception management. One
respondent said that pharmacists could
‘be more proactive in discussing LARCs
as an option for contraception with the
provision of emergency contraception’.
The report also identified unplanned
pregnancy as ‘a key health issue
for women in Australia and called
for increased Medicare funding for
contraception services, including the
extension of Medicare items to include
nurses working in GP clinics who insert
and remove different types of long-acting
reversible contraceptive devices.
Links Archive Australian Pharmacist May 2016 Australian Pharmacist July 2016 Navigation Previous Page Next Page